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Background: Knee osteoarthritis (OA) progression has been linked to increased peak external knee adduction
moments (KAMs). Although some trials have attempted to reduce pain and improve function in OA by reducing
KAMs with a wedged footwear insole intervention, KAM reduction has not been specifically controlled for in trial
designs, potentially explaining the mixed results seen in the literature. Therefore, the primary purpose of this trial is
to identify the effects of reduced KAMs on knee OA pain and function.
Methods/design: Forty-six patients with radiographically confirmed diagnosis medial knee OA will be recruited for
this 3 month randomized controlled trial. Recruitment will be from Alberta and surrounding areas. Eligibility criteria
include being between the ages of 40 and 85 years, have knee OA primarily localized to the medial tibiofemoral
compartment, based on the American College of Rheumatology diagnostic criteria and be classified as having a
Kellgren-Lawrence grade of 1 to 3. Patients will visit the laboratory at baseline for testing that includes dual x-ray
absorptiometry, biomechanical testing, and surveys (KOOS, PASE activity scale, UCLA activity scale, comfort visual
analog scale). At baseline, patients will be randomized to either a wedged insole group to reduce KAMs, or a waitlist
control group where no intervention is provided. The survey tests will be repeated at 3 months, and response to
wedged insoles over 3 months will be evaluated.
Discussion: This study represents the first step in systematically evaluating the effects of reduced KAMs on knee OA
management by using a patient-specific wedged insole prescription procedure rather than providing the same insole
to all patients. The results of this trial will provide indications as to whether reduced KAMs are an effective strategy for
knee OA management, and whether a personalized approach to footwear insole prescription is warranted.
Trial registration: NCT02067208.
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Arthritis is one of the most prevalent musculoskeletal
disorders, currently affecting 15% of people aged 15 years
and older (~4.6 million Canadians), with an economic
cost of $33 billion annually in Canada [1,2]. The most
common form is knee osteoarthritis (OA), affecting 16%* Correspondence: lewinson@ucalgary.ca
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unless otherwise stated.of adults over the age of 45 [3]. It is characterized by
degeneration of the knee joint cartilage, leading to severe
pain, stiffness and swelling [4]. Commonly, symptoms
will be severe enough to cause long-term disability [5,6].
Currently, the gold standard treatment for severe OA is
total joint arthroplasty (TJA) [7]. However, the majority
of OA patients may be more suited for conservative
management of OA, to either minimize symptoms in
the short term, or ultimately prevent progression of OA
to avoid the need for TJA.ral Ltd. This is an Open Access article distributed under the terms of the Creative
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interventions as they are generally low cost and relatively
easy to implement. Biomechanically, cross-sectional and
prospective studies have suggested that knee OA devel-
opment and progression are related to increased peak
external knee adduction moments (KAMs) during the
single-leg support phase of walking [4-6]. This increased
KAM is believed to induce large stress in the medial
compartment of the knee, which, over time, contributes
to cartilage degeneration, pain and ultimately OA [8].
Supporting this concept, increased KAMs have been
positively correlated with higher Kellgren Lawrence grades,
and cartilage loss over 12 months (KAM impulses), and
negatively correlated with tibial cartilage thickness [5,6,9].
Thus, a focus for knee OA prevention and management
has been to reduce these KAMs [4].
Across 13 international clinical guidelines for manage-
ment of knee OA, wedged insoles (i.e. insoles that elevate
either the lateral or medial aspect of the foot) have been
consistently recommended for disease management since
they can influence KAMs [10]. On average across patients,
laterally wedged insoles have been shown to reduce KAMs
and reduce pain, while medially wedged insoles tend to
increase KAMs; [4,11] however, when considering subject
specific reactions, 15-43% of patients, depending on the
study, receiving either a medial or lateral wedge will experi-
ence KAM changes that are completely opposite to the
group average result [12,13]. This means that every year,
thousands of North Americans with knee OA are being
prescribed an incorrect wedge resulting in increased
KAMs, and possibly accelerating and worsening their OA.
Interestingly, when reviewing past literature of major
randomized trials for knee OA, no study has actually
ensured that all patients experienced a reduction in KAMs
in the experimental insole group, and this has likely had a
large bias on study results [14,15]. Thus, it is no surprise
that a recent review has highlighted that large variability
exists across studies in terms of the effectiveness of lateral
wedge insoles [16]. Essentially, we still do not truly under-
stand how or if wedged insoles and reduced KAMs can
benefit patients with knee OA. Therefore a randomized
trial is urgently needed that assigns wedged insoles on
a personalized basis to ensure that KAMs are being
reduced. Thus, the primary purpose of this study is to
evaluate the effectiveness of a personalized wedged
insole intervention on pain in patients with medial knee
OA. Specifically, KAMs must be measured for each
participant to ensure KAM reduction occurs with the
intervention insole, rather than providing all patients
with the exact same insole and assume a constant
KAM effect as previous trials have done. This approach
of ensuring KAM reduction has never been attempted
before and so the results from this study will help
evaluate the true clinical benefit of KAM reduction,and also the true effectiveness of wedged insoles. It is
hypothesized that patients in the experimental group,
where KAMs have been reduced using an individually
prescribed wedged insole, will overall have greater im-
provements in pain and physical function over 3 months
compared to the control group.
Methods
Participant consent & ethical approval
Ethics approval for this study has been obtained from the
University of Calgary Conjoint Health Research and Ethics
Board (CHREB). In accordance with CHREB guidelines,
written consent will be obtained from each individual prior
to being enrolled in the study formally as a participant, and
prior to any testing.
Eligibility, recruitment and evaluation for inclusion
The trial will have two parallel groups, where participants
are randomly assigned to a waitlist control or experimental
arm for a study duration of 3 months (Figure 1). Patients
with painful radiographic medial knee osteoarthritis will
be recruited from either the University of Calgary Sport
Medicine Centre patient population (a Knee Osteoarthritis
clinic is part of the services provided by this centre) or the
Alberta Hip and Knee Arthroplasty clinics. Identified
patients will be approached for inclusion into the study
based on the inclusion/exclusion criteria described below.
If recruitment is too slow to meet study timelines, adver-
tisements of the project will be put into local newspapers
and to other media. In these cases, a phone assessment of
the volunteer will be undertaken for preliminary screening,
and the individual will be invited for a detailed assessment
by the study physician to determine their eligibility.
All patients considered eligible for the study must have
physician-diagnosed knee OA primarily localized to the
medial tibiofemoral compartment, based on the American
College of Rheumatology clinical and radiographic diag-
nostic criteria [17]. Patients showing lateral compartment
or patellofemoral OA in addition to medial knee OA will
still be considered eligible as long as the medial compart-
ment is the primary disease location and symptoms are
attributed to the medial compartment. In addition, patients
must be between the ages of 40–85 years of age, have
no history of viscosupplement injections within the past
6 months, cortisone injection within the past 3 months,
narcotic pain medication within the past 3 months, or use
of other footwear insoles or unloader knee braces within
the past 2 months, and must have a Kellgren-Lawrence
grade (a measure of OA severity) of 1 to 3, as determined
by a clinician, to avoid inclusion of end-stage OA patients
that may be more appropriate for surgery [18]. Patients
may continue to use anti-inflammatory medication or
acetaminophen for mild pain management if needed.
Those who meet the intrarticular injection criteria must
Figure 1 Flow of participants through the study.
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the 3-month study. Patients must also present with a
KOOS pain subscale score of 75 points or lower. This
will help ensure that all participants have at least mildly
painful knee OA. Any participant with recent (within
2 months) musculoskeletal or neuromuscular injury to the
lower extremity that could bias pain assessments or gait
analysis will not be considered eligible. For this reason,
patients who typically use a cane will also be excluded.Footwear insole interventions
Two footwear insole interventions will be utilized within
the experimental arm of this study: (1) the first is a medial
wedge insole placed within the participants own shoe.
The insole will be developed using a 3D printer, where
the wedge thickness is 0.5 mm on the lateral edge, and
6.5 mm on the medial edge. The insole will taper at the
metatarsal heads to a thickness of 4.5 mm to ensure a
comfortable fit within the participant’s shoe. A wedge
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has been shown to be large enough to influence knee me-
chanics, yet small enough to maintain comfort [14,19-21].
During testing and long term use, this insole will be placed
under the existing sock liner of the participant’s shoe. (2)
The second condition is a lateral wedge insole placed
within the participants own shoe. The insole will be devel-
oped using a 3D printer, where the thickness of the medial
edge is 0.5 mm and the thickness of the lateral edge is
6.5 mm, tapering to 4.5 mm beyond the metatarsal heads.
During testing and long term use, this insole will be placed
under the existing sock liner of the participant’s shoe. For
construction of the medial and lateral wedge, the wedge
will extend along the full length of the foot, creating
approximately 5–6 degree medial and lateral wedges [22].
All insoles will be produced by New Balance Athletic Shoe
Inc. (Boston, MA). The material utilized for the insoles is
stiff in compression, such that the wedge shape will be
maintained throughout the 3 month study; however, the
material is also flexible to ensure comfort within the shoe
during flexion of the metatarsal joints.
The authors must emphasize the relationship between
the intervention we intend to utilize (wedged insoles),
and the mechanical effect we aim to achieve (reduced
KAMs). It is this mechanical result (reduced KAMs) that
is suggested in the literature to affect knee OA – not
wedged insoles on their own. Thus it is critical to bear
in mind that the wedged insoles are simply a means to
achieve the desired mechanical outcome.
Recently, it has been reported by a meta-analysis that
future knee OA trials should utilize a flat insole as a
control condition [16]. The motivation for this claim was
based on the notion that this would control for placebo
effects. However, recent evidence has suggested that even
flat insoles can alter pressure distributions under the foot
during gait [23], and thus it remains a possibility that
KAMs could be influenced as well. Therefore, while flat
insoles may control for placebo effects, they may not con-
trol for gait biomechanics, which is the primary concern
of our trial. Consequently, the control condition for our
study will be the participant’s own footwear, as this will
control for gait biomechanics changes. Therefore, for
biomechanical reasons, the trial will not be placebo
controlled. In effort to ensure recruitment, compliance
and participant retention in our control condition, we will
utilize a waitlist control strategy, where we will indicate
that a 3 month wait is required prior to providing an
insole. After 3 months, we will provide control partici-
pants with access to a wedged insole, and continue to
monitor them for safety.
Laboratory testing protocol
All eligible participants will be invited to the laboratory
for baseline testing. At baseline, body metrics such asheight (m), mass (kg) and age (years) will be recorded, and
also basic clinical diagnostic data (eg. Kellgren-Lawrence
grade).
Body composition
Lean and fat mass will be evaluated at baseline using
Dual Energy X-Ray Absorptiometry (DXA, Hologic QDR
4500; Hologic, Bedford, MA), the clinical gold standard
for body composition.
Biomechanics
Eight Motion Analysis cameras (Motion Analysis Corp.,
Santa Rosa, CA) sampling at 240 Hz will record the 3D
trajectories of retroreflective markers placed over the
participants most symptomatic limb as they walk along a
20 m runway. A force platform (Kistler AG, Winterthur,
Switzerland) will collect ground reaction force data at a
frequency of 2400 Hz as the participant walks along the
runway. This will be done for 5 successful trials in each of
3 footwear conditions for each participant: (1) participant’s
own shoe (baseline condition), (2) participant’s own shoe
with the lateral wedge insole, and (3) participant’s own
shoe with the medial wedge insole. A successful trial is
defined as one where the participant lands with their most
symptomatic limb near the center of the force platform,
does not touch the force platform with their other limb,
and maintains a gait speed of 1.3 ± 0.07 m/s as measured
by two photocells.
Kinetic and kinematic data will be filtered using 4th
order Butterworth low-pass filters with cut-off frequencies
of 50 Hz and 12 Hz, respectively. KAMs during stance will
be calculated using an inverse dynamics approach, and the
peak KAM (first peak) will be identified for each trial
[4,19]. The average KAM across trials for each footwear
condition will then be calculated and represented as a
percent change from the baseline condition value. The
KAM impulse (integral of KAMs with respect to time)
and Varus thrust (maximum mediolateral displacement of
knee joint center from touchdown) [24] and the KAM
impulse (integral of KAMs with respect to time) [25]
will also be calculated as these variables have also been
shown to be related to knee OA [6,24]. At the baseline
visit, biomechanical testing and DXA scans will be per-
formed and survey information will be collected. After
determining the peak KAMs for all three conditions,
the percent change in KAM will be determined for the
medial and lateral wedge conditions.
Survey protocol
Patient history
Detailed musculoskeletal injury histories will be taken
for each participant. This will be done on a recall basis,
and will specifically request that patients outline any
previous traumatic, acute knee injuries (e.g. meniscal
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femoral fractures, plica, knee ligament damage including
avulsion tears, or any large impacts to the knee causing
excessive bruising or swelling), surgical procedures on
the knee, or any history of heavy loading activities (e.g.
American football, running, ski jumping etc.).
KOOS
The Knee Injury and Osteoarthritis Outcomes Score
(KOOS) is based on the Western Ontario and McMaster
Universities (WOMAC) Arthritis Index– a survey that is
both valid and reliable for measurement of pain, function
and stiffness in OA populations [26-32]. Additionally, the
KOOS includes subscales that can evaluate function in
activities of daily living and during more rigorous activity,
allowing it to be sensitive to differences in activity between
individuals. The five KOOS components include: pain,
symptoms, function in daily living, function in sport and
recreation, and knee related quality of life. The KOOS has
been extensively validated and can be used over long
periods of time, allowing for possibility of long-term
follow-up of the recruited patient cohort [33-37]. The
KOOS will be administered at baseline, and at 1 month,
2 months and 3 months follow-up.
Physical activity
Two physical activity scales will be used in this study.
The first is the UCLA physical activity scale. This scale
provides a global measure of activity, and is commonly
used in osteoarthritis populations undergoing arthroplasty
[38]. The second is the Physical Activity Scale for the
Elderly (PASE). PASE will be used to evaluate the type and
duration of recreational and occupational physical activity
of the previous week [39]. This scale was originally devel-
oped and validated for individuals over the age of 55 years,
which is appropriate for the majority of the knee OA
population. The purpose of the physical activity scales
are to identify whether physical activity levels generally
increased, decreased or remained constant during the
study for experimental and control participants. The tests
will be administered at baseline, and at 1 month, 2 months
and 3 months follow-up.
Adherence
At baseline, participants will be asked to refrain from
utilizing any alternate therapies during the study period
(aside from anti-inflammatory or acetaminophen medica-
tion), and asked to utilize the prescribed footwear condition
as frequently as possible during the day. While not an
exclusion criteria of this study, participants will be asked to
try and always use the insole in the same shoe tested at
baseline. We will conduct a survey at 1 month, 2 months
and 3 months follow-up to evaluate participant adherence
to the intervention, which will include recall of the numberof hours per day using the assigned insole over the past
week, recall of the number of times in the past week a
different shoe from baseline was used with the insole,
and recall of the number of times alternate allowable
therapies were used, such as targeted exercise for OA
or anti-inflammatory and acetaminophen medications.
Use of therapies that are considered as exclusion criteria
(i.e. viscosupplementation, knee braces, narcotic pain
medication), will also be recorded.
Comfort
Some studies have suggested that footwear comfort may
be an important variable in determining the effectiveness
of a footwear intervention on pain management [40].
Therefore, we will administer a paper-based 100 mm vis-
ual analog scale with the terms “extremely comfortable”
and “extremely uncomfortable” as anchors at 100 mm
and 0 mm, respectively. The tests will be administered
on paper at baseline.
Randomization
Following the baseline laboratory and survey testing,
participants will be randomized into one of two study
arms: (1) a KAM-reduction experimental group (KAM-R),
or (2) a waitlist control group. In the KAM-R group,
participants will be given either a medial or lateral wedge
insole (whichever insole reduces KAMs more for each
individual participant) to put inside their own shoe and
use for 3 months. In the waitlist control group, partici-
pants will be asked to continue using their own shoes for
a period of 3 months, and following this will be provided
with access to a wedged insole (whichever reduces KAMs
more based on baseline data collection).
Participants will be randomized using a multi-block-
randomization procedure into either the KAM-R or wait-
list control group. Specifically, a separate block sequence
will be used for males and females to ensure an even
sex distribution across groups. A block size of 6 will be
used for each, and the sequence will be determined
from a random number generator.
The one exception to this block randomization proced-
ure is that if neither wedged insole produces a KAM
reduction, the participant will be excluded from the main
study altogether. This scenario will not be common, as
most people do experience a large change in KAMs with
one of the two wedged insole types, but this strategy will
ensure that all participants in the KAM-R and waitlist
control groups are all biomechanically suitable for a
wedged insole intervention. Thus, neither group will con-
tain biomechanical non-responders to wedged insoles.
Blinding
Knowledge of the participant’s KAM change is required
to ensure that the study sample consists entirely of those
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insole type. We will randomize patients to either the
KAM-R or control group prior to knowing the KAM
results and prior to any data collection. After collecting
biomechanical data, KAM results will be assessed to
verify that the participant experienced a KAM reduction
in at least one wedged insole type. As described previ-
ously, in cases where the participant does not experience a
KAM reduction with either insole, they will be excluded
from the main study. Thus our knowledge of KAM
changes will not affect our initial randomization, and only
be used as a verification tool. Although researchers will
be aware of each participant’s study group following
randomization (in order to assign the participants in the
KAM-R group an insole to take home), the researchers
will be blinded during future survey data collection and
data analysis as identifying information will be stripped
by an independent researcher and replaced with unique
patient ID numbers and numerical values for group
allocation. Those involved in statistical analysis will be
blinded to the group allocation and outcomes during
data analysis. All KAM-R participants will be aware as
to which condition they have been assigned, based on
knowing that they have received an insole. All control
condition participants will be aware that they have not
received an insole at baseline, but will receive an insole
at 3 months. Thus, the study will not be blinded at base-
line data collection; however, follow-up data collection
and data analysis will be blinded to the researchers.
Primary outcome measures
The primary outcome measure in this study will be the
KOOS pain score (0–100 points). This measure will
allow us to identify the overall treatment effect of the
wedged insole intervention over the 3-month follow-up
period.
Secondary outcome measures
Secondary outcome measures include the remaining
four KOOS subsection scores (symptoms, function (daily
living), function (sport & recreation activities), quality of
life; 0–100 points each), PASE (0-400+ points) and
UCLA (0–10 points) physical activity scores, peak KAM
(Nm), KAM impulse (Nms), varus thrust (mm), adiposity
(%), footwear comfort (0–100 mm) and the general inter-
vention adherence survey. In addition, we will use Kellgren-
Lawrence grade (grade 1–3) in secondary analyses.
Sample size calculation
Sample size calculations were performed based on our
primary outcome variable, the KOOS pain score, with a
desired power of 80% and a significance level of 0.05
using the statistical software Stata version 11.2. Given
the early stage of research concerning the effects andinteractions of load reduction, and different OA subtypes
on treatment outcome, we chose to only conduct sample
size calculations on a repeated measures basis for within
group comparisons. Based on the results of this trial,
sample sizes may be expanded to increase statistical power
in order to make comparisons between the control and
KAM-R group.
The minimum perceptible clinical improvement and
minimum detectible change in KOOS score has been
reported to be about 13.4 points [33,41]. Using a base-
line KOOS pain score of 57.3 points [42] and a standard
deviation of 15 points [41], to detect a minimal clinically
important improvement of 13.4 points within each group,
20 participants are required in each group, or 40 total
participants. To account for a potential dropout rate of
15%, we will recruit a minimum of 46 participants.
Statistical analysis
Descriptive analyses will be performed on all variables.
Outcome measures data will be plotted to assess trends
of change over the 3 months.
Within group analyses
All data will be analyzed on an intention to treat basis.
Changes from baseline to 3 months will be assessed within
groups for ordinal data (UCLA score) using Wilcoxon
Signed Rank test (α = 0.05). KOOS subsection scores and
PASE scores will be compared between baseline and at
3 months using paired-samples t-tests (α = 0.05). KAMs,
KAM impulse, varus thrust, and footwear comfort will be
compared between the neutral shoe and assigned wedged
insole condition at baseline for the KAM-R group using
paired-samples t-tests (α = 0.05). All tests will be two-
tailed, except in the case of KAMs and KAM impulse,
where one-tailed tests will be used. The reason for this is
that KAM reduction is strictly controlled in this study
and so KAM and KAM impulse reductions are the only
possible outcome.
A multivariable linear regression (α = 0.05) will also be
conducted on the KAM-R group to evaluate whether KAM
reduction, KAM impulse, varus thrust and footwear com-
fort can predict change in pain over 3 months. Covariates
tested in these four models will include adiposity and
Kellgren-Lawrence grade.
Between group analyses
Ordinal data from UCLA scores and Kellgren-Lawrence
grades will be compared at baseline and at 3 months
(UCLA score only) between the control and KAM-R
group using Mann–Whitney U tests (α = 0.05). KOOS
subsection scores, PASE scores, KAMs, KAM impulse,
varus thrust, adiposity, footwear comfort, and adherence
will be compared at baseline between the KAM-R and
control group using a MANOVA test (α = 0.05) with
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over 3 months will also be assessed between groups using
a MANOVA (α = 0.05) with independent-samples t-tests
for post-hoc analysis. All tests will be two-tailed, except in
the case of KAMs and KAM impulse, where one-tailed
tests will be used. The reason for this is that KAM reduc-
tion is strictly controlled in this study and so a reduction in
KAMs and KAM impulse is the only possible outcome. It
should be noted that all between group comparisons are
exploratory analyses, as we may not be powered to detect
any significant differences between groups.
Discussion
The primary goal of this randomized controlled trial is to
identify the influence of reduced KAMs on management
of knee OA symptoms. In this study, wedged footwear
insoles will be used as the intervention to induce reduced
KAMs. Wedged insoles are a relatively inexpensive and
easy-to-use intervention, and have been a recommended
management strategy in numerous international clinical
guidelines for OA. However, some randomized trials
conducted on wedged insoles have shown inconsistent
results. The primary reason for this is that previous
studies used exclusively a lateral wedge insole and did
not test each participant’s biomechanics to ensure that
the lateral wedge actually reduced KAMs. Indeed, it has
been found in numerous studies that lateral wedges may
in fact increase KAMs during gait for some participants,
which could induce OA worsening, and wash out any
actual treatment effects of reduced KAMs that may be
observed in other participants [12,13]. Thus, in our study,
we are testing both medial and lateral wedge insoles, and
prescribing the insole that reduces KAMs the most. This
will ensure that all participants in our KAM-R group
experience reduced KAMs.
Another reason why other wedged insole studies have
shown mixed results on OA management is that these
studies used inadequate control interventions. Specifically,
some studies have given all control participants a flat
neutral insole. Other studies have provided a new shoe
to all participants as a control condition [40]. While in
theory this is appropriate as an attempt to protect against
placebo effects and provided a method for blinding, it
does carry the possibility that some participants will
experience altered KAMs during gait. For instance,
McCormick et al. [23] have shown that control insoles
alter pressure distributions relative to a no insole condi-
tion, and this pressure shift could affect KAM magnitude
[4]. Therefore, in our study, we have chosen to utilize the
participant’s own shoe as a control condition to ensure
biomechanics remain unchanged. Our regression analyses
will provide some insight into whether placebo effects do
exist with wedged insoles. For instance, if the slope of the
line of best fit is not near zero, it would suggest thatchange is pain is related to a reduction in KAM regardless
of whether a placebo effect exists or not.
Conclusions
In conclusion, this will be the first study to isolate the
effects of reduced KAMs on symptom management for
patients with mild to moderate medial knee OA over a
follow-up period of 3 months. This study could therefore
have strong clinical implications regarding personalized
prescription of wedged insoles.
Clinical relevance and importance
This randomized controlled trial will help provide insight
to optimize clinical management strategies for patients with
mild to moderate medial knee OA by evaluating the effects
of a knee joint load-reducing intervention. These results
could have immediate implications on clinical practice, spe-
cifically the efficacy of knee joint load-reducing insoles, and
also help identify new areas of study for basic scientists.
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